Publish in this journal
Journal Information
Vol. 63. Issue 2.
Pages 241-242 (February 2010)
Share
Share
Download PDF
More article options
Vol. 63. Issue 2.
Pages 241-242 (February 2010)
DOI: 10.1016/S1885-5857(10)70046-3
Full text access
Severe Septal Hypertrophy: Is It Necessarily a Contraindication for the Transcatheter Implantation of an Edwards-Sapien Prosthesis?
Hipertrofia septal severa: ¿es necesariamente una contraindicación para la implantación transcatéter de prótesis de Edwards-Sapien?
Visits
6566
Raúl Morenoa, Luis Calvoa, Eulogio Garcíab, David Dobarroa
a Unidad de Cardiología Intervencionista, Hospital Universitario La Paz, Madrid, Spain
b Unidad de Cardiología Intervencionista, Hospital Clínico San Carlos, Madrid, Spain
This item has received
6566
Visits
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

To the Editor,

Aortic stenosis is the most frequent valvular heart disease in the developed world.1 The natural history of severe symptomatic aortic stenosis (SSAS) offers little hope of survival and valve substitution surgery is the only effective treatment.2 However, 30%-40% of patients with SSAS are not operated as they present too high an estimated surgical risk.3 Survival and quality of life are limited in these patients. Percutaneous balloon valvuloplasty was initially considered an alternative therapy but it offers very poor mid-term results.4 Recently, percutaneous implantation of prosthetic aortic valves (PIAP) has been introduced as a valid option for patients with SSAS and prohibitive surgical risk.5-8

One contraindication of PIAP is severe interventricular septal hypertrophy because the prosthesis may be displaced and migrate during implantation. We describe a simple modification to aortic prosthesis deployment that has enabled us to treat PIAP successfully (Edwards-Sapien prosthetic valve) in 2 patients with inoperable SSAS and severe interventricular septal hypertrophy.

Two patients with SSAS (men, aged 79 and 90 years) were referred for PIAP with Edwards-Sapien prostheses (Edwards Lifesciences Inc, Irvine, California, US). The patient selection process8,9 revealed no contraindication for the technique other than severe interventricular septal hypertrophy (18 mm and 19 mm, respectively). We decided to proceed with the intervention.

In both patients, we implanted an 26 mm Edwards-Sapien prosthesis, an expandable aortic valve balloon prosthesis delivered via a stainless steel stent, with 3 bovine pericardial valves. It is assembled in the interventional cardiology laboratory with a 30 mm long balloon. The 26 mm valve is 16 mm long, and its location in the middle of the balloon is recommended, leaving 7 mm of balloon on either side of the prosthesis. Severe interventricular septal hypertrophy is considered a contraindication for PIAP because when balloon inflation—and therefore, implantation—takes place, the prosthesis may be displaced by the septum and migrate towards the ascending aorta. In these 2 patients, we minimized contact between the balloon and the interventricular septum by positioning the prosthetic valve asymmetrically, more distal, leaving only 3-4 mm of balloon on the intraventricular side of the prosthesis (Figure). Thus, we were able to implant the prostheses successfully in both 2 patients, without displacement, with optimal expansion, and without periprosthetic insufficiency. Both patients were discharged without complications.

Figure 1.A: deployment of the prosthesis in a patient without severe interventricular septal hypertrophy. The prosthesis is positioned symmetrically in the balloon. B: patient with severe interventricular septal hypertrophy. To minimize contact between the balloon and the interventricular septum, the valve is located in the balloon asymmetrically, more distal, to leave only 3-4 mm of the balloon on the ventricular side of the prosthesis.

These 2 patients described show severe interventricular septal hypertrophy, not necessarily a contraindication for transcatheter aortic valve implantation (TAVI) of Edwards-Sapien prostheses. This technique can only be recommended for patients with severe interventricular septal hypertrophy, given that the risk of prosthesis displacement in most patients is very low when the prosthesis is located symmetrically in the balloon.

Bibliography
[1]
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M..
Burden of valvular heart disease: a population-based study..
[2]
Task Force on the Managemente of Valvular Heart Disease of the European Society of Cardiology..
Guidelines on the management of valvular heart disease..
Eur Heart J, 428 (2007), pp. e1-39
[3]
Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al..
A prospective survey of patients with valvular heart disease in Europe: The EuroHeart Survey on Valvular Heart Disease..
Eur Heart J, 24 (2003), pp. 1231-43
[4]
McKay RG..
The Mansfield Scientific Aortic Valvuloplasty Registry: overview of acute hemodynamic results and procedural complications..
J Am Coll Cardiol, 17 (1991), pp. 189-92
[5]
Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Nercolini D, et al..
Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience..
J Am Coll Cardiol, 47 (2006), pp. 1214-23
[6]
Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, et al..
Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis..
Circulation, 116 (2007), pp. 755-63
[7]
Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, Wenaweser P, et al..
Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second and current third generation self-expanding CoreValve prosthesis..
J Am Coll Cardiol, 50 (2007), pp. 69-76
[8]
Moreno R, Calvo L, Filgueiras D, López T, Sánchez-Recalde A, Jiménez-Valero S, et al..
Implantación percutánea de prótesis valvulares aórticas en pacientes con estenosis aórtica severa sintomática rechazados para cirugía de sustitución valvular..
Rev Esp Cardiol, 61 (2008), pp. 1215-9
[9]
García E, Pinto AG, Sarnago F, Pello AM, Paz M, García-Fernández MA, et al..
Implantación percutánea de prótesis valvular aórtica: experiencia inicial en España..
Rev Esp Cardiol, 61 (2008), pp. 1210-4
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.